Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
A federal appeals court has upheld a $142 million jury verdict in a case involving Pfizer's epilepsy drug Neurontin, and opened the door for potentially ENT TO: ALL PERSONS OR ENTITIES WHO HAVE PURCHASED NEURONTIN DIRECTLY FROM PFIZER, INC. AND WARNER-LAMBERT AT ANY TIME DURING THE PERIOD OF DECEMBER 11, 2002, THROUGH AUGUST 31, 2008 AND WHO HAVE ALSO PURCHASED GENERIC GABAPENTIN, EXCLUDING: (1) GOVERNMENTAL ENTITIES; (2) DEFENDANTS AND THEIR OFFICERS, DIRECTORS, MANAGEMENT AND EMPLOYEES, SUB A $190 million settlement has been reached in New York in a consumer fraud class action lawsuit pending against Pfizer which alleges the pharma giant engaged in tactics to delay market entry of generic versions of its epilepsy drug Neurontin. Legally Reviewed Fact-Checked What Is Neurontin? Gabapentin, an anti-seizure drug marketed by Pfizer Laboratories in the United States under the trademark name Neurontin, has been the subject of numerous claims of malfeasance in gabapentin side effects lawsuits, with the Pfizer company intentionally and knowingly marketing the medication for uses not approved by the FDA (Food and Drug In 2004, Pfizer agreed to pay $430 million in a DOJ settlement and pleaded guilty to two violations of the Food, Drug and Cosmetic Act for marketing the drug Neurontin, also known as And it's the second settlement of Neurontin-related claims in less than 6 weeks. On April 21, Pfizer said it would pay $190 million to settle a federal antitrust lawsuit claiming that the company It resolves allegations in a decade-old civil lawsuit that Pfizer and its Warner-Lambert Co unit sold Neurontin for uses for which it was neither approved by the U.S. Food and Drug Administration American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. (hereinafter together “Pfizer”) have agreed to pay $2.3 billion, the largest health care fraud settlement in the history of the Department of Justice, to resolve criminal and civil liability arising from the illegal promotion of certain pharmaceutical products. Pfizer, the world's largest drug maker, pleaded guilty on 13 May to numerous civil and criminal charges for illegally promoting the off-label use of gabapentin (Neurontin). It has agreed to pay a $240m (£136m; €200m) criminal fine and $152m to state and federal healthcare programmes. The fine is the second largest given in the industry. -- In the largest health care fraud settlement in history, pharmaceutical giant Pfizer must pay $2.3 billion to resolve criminal and civil allegations that the company illegally promoted uses of four of its drugs, including the painkiller Bextra, the U.S. Department of Justice announced Wednesday. Redirecting to Pharmaceutical company Pfizer Inc. (Pfizer), on behalf of its wholly-owned subsidiary Biohaven Pharmaceutical Holding Company Ltd. (Biohaven), has agreed to pay $59,746,277 to resolve allegations that, prior to Pfizer’s acquisition of the company, Biohaven knowingly caused the submission of false claims to Medicare and other federal health care programs by paying kickbacks to Los Angeles, CA: A $325 million preliminary settlement has been reached by Pfizer Inc and Warner-Lambert Co. LLC and plaintiffs who filed a consumer fraud class action lawsuit over the marketing The U.S. Supreme Court on Monday left intact a $142 million jury verdict against Pfizer Inc over the marketing of the epilepsy drug Neurontin. Pfizer pleads guilty and agrees to pay $430 million to resolve criminal and civil charges that it paid doctors to prescribe epilepsy drug Neurontin to patients with ailments that drug was not One of the most notable cases involved Pfizer, the company responsible for Neurontin, a brand name version of Gabapentin. In 2004, Pfizer reached a $430 million settlement with the Department of Justice (DOJ) after pleading guilty to two violations of the Food, Drug and Cosmetic Act. Plaintiffs alleged that through its scheme, Pfizer was able to maintain its monopoly in the market for gabapentin anhydrous, improperly causing direct purchasers of Neurontin to pay artificially inflated prices for gabapentin products. Neurontin was launched into the marketplace in February of 1994; from mid-1995 to at least 2001, the growth of off-label sales was tremendous. While not all of these sales were the consequence of Warner-Lambert’s illegal marketing, the marketing scheme was very successful in increasing Neurontin prescriptions for unapproved uses. The plaintiffs in the Neurontin class action lawsuit alleged that Pfizer delayed competition from generic producers of the drug, gabapentin anhydrous, which Pfizer sold under the name Neurotin, by exercising a monopoly over the medicine. Federal prosecutors on Thursday announced that Pfizer has agreed to plead guilty to criminal wrongdoing and pay a settlement of $430 million in a whistleblower lawsuit alleging that the Parke-Davis unit of Pfizer subsidiary Warner-Lambert illegally encouraged physicians to prescribe the epilepsy drug Neurontin to treat conditions other than
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |